(Q45857203)

17 December 2017

title

TRUST trial: BAY 86-6150 use in haemophilia with inhibitors and assessment for immunogenicity (English)

1 reference

17 December 2017

0 references

J Mahlangu

1

1 reference

17 December 2017

P Paz

2

1 reference

17 December 2017

M Hardtke

3

1 reference

17 December 2017

F Aswad

4

1 reference

17 December 2017

J Schroeder

5

1 reference

17 December 2017

publication date

8 August 2016

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

22

1 reference

17 December 2017

issue

6

1 reference

17 December 2017

page(s)

873-879

1 reference

17 December 2017

Guidelines for the management of hemophilia

cites work

1 reference

Inhibitors: our greatest challenge. Can we minimize the incidence?

21 January 2018

1 reference

Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice

21 January 2018

1 reference

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study

21 January 2018

1 reference

Phase I, randomized, double-blind, placebo-controlled, single-dose escalation study of the recombinant factor VIIa variant BAY 86-6150 in hemophilia

21 January 2018

1 reference

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)

21 January 2018

1 reference

Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity.

21 January 2018

1 reference

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

21 January 2018

1 reference

NetMHCIIpan-2.0 - Improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure.

21 January 2018

1 reference

Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics

21 January 2018

1 reference

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells

21 January 2018

1 reference

Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene

21 January 2018

1 reference

Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors

21 January 2018

1 reference

A new report of FVII-inhibitor in a patient suffering from severe congenital FVII deficiency

21 January 2018

1 reference

Predicting dosing advantages of factor VIIa variants with altered tissue factor-dependent and lipid-dependent activities

21 January 2018

1 reference

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors

21 January 2018

1 reference

Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa

21 January 2018

1 reference

Molecular analysis of the genotype-phenotype relationship in factor VII deficiency

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HAE.12994

1 reference

17 December 2017

1 reference

17 December 2017